Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies
RJ Sullivan, JS Weber - Nature reviews Drug discovery, 2022 - nature.com
The immune-related adverse events associated with treatment with immune checkpoint
inhibitors result in significant morbidity for patients as well as considerable cost to the health …
inhibitors result in significant morbidity for patients as well as considerable cost to the health …
Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors–a systematic review and meta-analysis
S Hussaini, R Chehade, RG Boldt, J Raphael… - Cancer Treatment …, 2021 - Elsevier
Background The use of immune checkpoint inhibitors (ICIs) has become standard therapy in
many tumor sites. The aim of this study is to systematically review the literature to determine …
many tumor sites. The aim of this study is to systematically review the literature to determine …
Association of immune-related adverse events with efficacy of atezolizumab in patients with non–small cell lung cancer: pooled analyses of the phase 3 IMpower130 …
MA Socinski, RM Jotte, F Cappuzzo, M Nishio… - JAMA …, 2023 - jamanetwork.com
Importance Immune-related adverse events (irAEs) arising from immune checkpoint inhibitor
(ICI) cancer therapy may potentially predict improved outcomes. Objective To evaluate the …
(ICI) cancer therapy may potentially predict improved outcomes. Objective To evaluate the …
[HTML][HTML] Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
MZ Wojtukiewicz, MM Rek, K Karpowicz… - Cancer and Metastasis …, 2021 - Springer
The treatment of cancer patients with immune checkpoint inhibitors (ICI)(anti-CTLA-4, anti-
PD-1, anti-PD-L1, combined therapy anti-PD-1/PD-L1 with anti-CTLA-4) has without doubt …
PD-1, anti-PD-L1, combined therapy anti-PD-1/PD-L1 with anti-CTLA-4) has without doubt …
[HTML][HTML] Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
A Cortellini, M Tucci, V Adamo, LS Stucci… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Concomitant medications, such as steroids, proton pump inhibitors (PPI) and
antibiotics, might affect clinical outcomes with immune checkpoint inhibitors. Methods We …
antibiotics, might affect clinical outcomes with immune checkpoint inhibitors. Methods We …
[HTML][HTML] Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta …
X Zhou, Z Yao, H Yang, N Liang, X Zhang, F Zhang - BMC medicine, 2020 - Springer
Background A number of studies have reported an association between the occurrence of
immune-related adverse events (irAEs) and clinical efficacy in patients undergoing treatment …
immune-related adverse events (irAEs) and clinical efficacy in patients undergoing treatment …
[HTML][HTML] Obesity, type 2 diabetes, and cancer risk
T Scully, A Ettela, D LeRoith, EJ Gallagher - Frontiers in oncology, 2021 - frontiersin.org
Obesity and type 2 diabetes have both been associated with increased cancer risk and are
becoming increasingly prevalent. Metabolic abnormalities such as insulin resistance and …
becoming increasingly prevalent. Metabolic abnormalities such as insulin resistance and …
Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors
Importance Immune-related adverse events (irAEs) secondary to immune checkpoint
inhibitor (ICI) therapy reportedly improve overall survival (OS) in patients with non–small cell …
inhibitor (ICI) therapy reportedly improve overall survival (OS) in patients with non–small cell …
Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis
YMM Cheung, W Wang, B McGregor… - Cancer Immunology …, 2022 - Springer
Background There is growing evidence suggesting that the occurrence of immune-related
adverse events (irAEs) may be a predictor of immune checkpoint inhibitor efficacy. Whether …
adverse events (irAEs) may be a predictor of immune checkpoint inhibitor efficacy. Whether …
[HTML][HTML] Association of immune related adverse events with efficacy of immune checkpoint inhibitors and overall survival in cancers: a systemic review and meta …
Y Fan, W Xie, H Huang, Y Wang, G Li, Y Geng… - Frontiers in …, 2021 - frontiersin.org
Objectives Immune checkpoint inhibitors (ICIs) have brought impressive benefits to cancer
patients, however often accompanied with immune-related adverse events (irAEs). We …
patients, however often accompanied with immune-related adverse events (irAEs). We …